Seasonal Allergic Conjunctivitis
📧 Sign up to get email alerts when something new happens for Seasonal Allergic Conjunctivitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-25Clinical Trial Update: Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis [Phase 2]
Phase 2 clinical trial evaluating TL-925 for seasonal allergic conjunctivitis is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-07-01Clinical Trial Update: Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis [Phase 3]
Phase 3 trial evaluating a fixed-dose combination of brimonidine tartrate and ketotifen fumarate for seasonal allergic conjunctivitis has co…
-
FDA approval · 2025-04-15FDA Approved: PATADAY ONCE DAILY RELIEF — Supplemental Application (Alcon Laboratories, Inc.)
FDA approved a supplemental application for PATADAY ONCE DAILY RELIEF (olopatadine hydrochloride) from Alcon Laboratories, expanding the lab…
-
CLINICAL_TRIALS trial_result · 2025-04-08Clinical Trial Update: A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis [Phase 1, Phase 2]
This clinical trial update reports results from a Phase 1/Phase 2 methodology development environmental study of reproxalap in subjects with…
-
CLINICAL_TRIALS trial_result · 2025-02-24Clinical Trial Update: A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber [Phase 1, Phase 2]
This clinical trial update reports that the Reproxalap study in seasonal allergic conjunctivitis completed and results were posted on Februa…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-01-28FDA Approved: LOTEPREDNOL ETABONATE — Supplemental Application (ARMAS PHARMACEUTICALS INC.)
FDA approves a supplemental application for Loteprednol Etabonate from Armas Pharmaceuticals Inc. under ANDA 212080, finalizing the status o…
-
FDA approval · 2024-12-18FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Somerset Therapeutics, LLC)
FDA approved Somerset Therapeutics' original application for olopatadine hydrochloride ophthalmic solution as a generic treatment for allerg…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis. [Phase 3]
Phase 3 INVIGORATE trial for seasonal allergic conjunctivitis has completed and the results have been posted.
-
CLINICAL_TRIALS trial_result · 2024-01-19Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients [Phase 3]
Phase 3 trial completed evaluating the efficacy and safety of epinastine hydrochloride eye drops for seasonal allergic conjunctivitis in Chi…
-
CLINICAL_TRIALS trial_result · 2022-10-26Clinical Trial Update: Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis [Phase 4]
Phase 4 clinical trial comparing Hylo-Dual to Patanol in children with seasonal allergic conjunctivitis and vernal conjunctivitis.
-
FDA approval · 2021-02-10FDA Approved: LOTEPREDNOL ETABONATE — Original Application (ARMAS PHARMACEUTICALS INC.)
FDA approved the original application for Loteprednol etabonate ophthalmic suspension from Armas Pharmaceuticals, establishing the generic c…
-
FDA approval · 2020-12-18FDA Approved: OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION — Supplemental Application (Bausch & Lomb Incorporated)
FDA approves a supplemental application for olopatadine hydrochloride ophthalmic solution by Bausch & Lomb, updating the product's approval.
-
CLINICAL_TRIALS trial_result · 2020-09-14Clinical Trial Update: Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients [Phase 2]
Phase 2 trial assessing safety and efficacy of Bepotastine Besilate Ophthalmic Solution for seasonal allergic conjunctivitis completed with …
-
FDA approval · 2020-08-06FDA Approved: OLOPATADINE HYDROCHLORIDE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application from Apotex Corp. for olopatadine hydrochloride (generic ophthalmic antihistamine). The approval cov…
-
FDA approval · 2020-01-28FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals LLC)
FDA approves the original application for olopatadine hydrochloride, a generic antihistamine used to treat allergic conjunctivitis.
-
CLINICAL_TRIALS trial_result · 2019-11-19Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% [Phase 4]
Phase 4 trial evaluating the safety and efficacy of Lotemax Ophthalmic Suspension 0.5% has completed.
-
FDA approval · 2018-06-06FDA Approved: PRED FORTE — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for PRED FORTE (prednisolone acetate ophthalmic suspension) submitted by Allergan, Inc.
-
CLINICAL_TRIALS trial_result · 2018-02-05Clinical Trial Update: Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis [Phase 4]
Phase 4 clinical trial update on non-pharmaceutical treatment for seasonal allergic conjunctivitis focusing on hypersensitivity conditions; …
-
FDA approval · 2017-06-28FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (GLENMARK THERAPEUTICS INC., USA)
FDA approves Glenmark's generic olopatadine hydrochloride ophthalmic solution for allergic conjunctivitis in an Original Application.
-
FDA approval · 2017-01-31FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved OLOPATADINE HYDROCHLORIDE ophthalmic solution under an Original Application for allergic conjunctivitis. The applicant is Padag…
-
CLINICAL_TRIALS trial_result · 2015-10-08Clinical Trial Update: AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis [Phase 3]
Phase 3 trial of AGN-229666 ophthalmic solution for seasonal or perennial allergic conjunctivitis has completed with results posted.
-
FDA approval · 2015-06-30FDA Approved: PATADAY TWICE A DAY RELIEF — Supplemental Application (Alcon Laboratories, Inc.)
FDA approved a supplemental application for Pataday Twice a Day Relief (olopatadine hydrochloride) by Alcon Laboratories, Inc.
-
FDA approval · 2015-01-30FDA Approved: PATADAY ONCE DAILY RELIEF — Original Application (Alcon Laboratories, Inc.)
FDA approved Pataday Once Daily Relief (olopatadine hydrochloride) from Alcon Laboratories in an Original Application for the treatment of a…
-
FDA approval · 2013-12-16FDA Approved: LOTEPREDNOL ETABONATE — Supplemental Application (Bausch & Lomb Americas Inc.)
The FDA approved a supplemental application for Loteprednol Etabonate (Lotemax) from Bausch & Lomb Americas Inc.
-
CLINICAL_TRIALS trial_result · 2013-09-17Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model. [Phase 2]
Phase 2 study of Mati Therapeutics' olopatadine-PPDS for ragweed-induced seasonal allergic conjunctivitis in an environmental exposure chamb…